Why it matters: The company is working in one of biotech’s toughest markets: new antibiotics. Its lead programme targets Gram-negative bacteria by inhibiting lipopolysaccharide (LPS) synthesis – a critical component of the bacterial outer membrane and a pathway not exploited by approved antibiotics.
Backstory: smartbax’s lead compound class was in-licensed from fellow German company AiCuris in January 2026. The asset originated from a screening programme run by AiCuris with the Max Planck Institute of Molecular Physiology in Dortmund.
- The company says the programme has shown in vivo proof of concept against multidrug-resistant Gram-negative strains, including WHO priority pathogens such as E. coli, K. pneumoniae and Enterobacteriaceae. It also reports nanomolar target inhibition and data supporting potential oral bioavailability.
- smartbax is also pursuing secondary antibacterial strategies aiming to activate bacterial hydrolases, triggering what the company describes as bacterial self-digestion. The approach could also be useful in difficult-to-treat biofilms.
By the numbers: smartbax first closed its pre-Series A round at €4.7m in October 2025, led by Anobis Asset and Bayern Kapital, with participation from UnternehmerTUM Funding for Innovators, HTGF and Boehringer Ingelheim Venture Fund. At the time, the company said a second closing remained open to investors.
- The initial funding was intended to move the LPS inhibitor through preclinical development while also supporting smartbax’s earlier-stage platform of small-molecule hydrolase activators.
- The additional €1.6m extension of the round comes from a Frankfurt-based family office, according to a statement from smartbax.
What they’re saying: “This second closing provides the resources to advance our lead program through IND filing, which will mark an important step in the maturation of our pipeline,” said Dr. Robert Macsics, CEO of smartbax.
Sign up for our newsletter!
.webp&w=280&h=180)
